STAT+: What does DeGette’s loss mean for pharma?

STAT PlusNewsletterD.C. Diagnosis What does DeGette’s loss mean for pharma? You’re reading STAT’s D.C. Diagnosis newsletter Manage alerts for this article Email this article Share this article By John WilkersonJuly 2, 2026 Washington Correspondent John Wilkerson[email protected]John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. RFK Jr. said on Fox News that he’ll leave raccoons alone “for the moment.” Send news tips and ideas for roadkill excursions to [email protected] or John_Wilkerson.07 on Signal.Advertisement DeGette’s loss is a mixed bag for drug industry The drug industry will lose a key Democratic lawmaker who was knowledgeable about the industry, if not always a friend. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, Congress, HHS, Pharmaceuticals, Policy, STAT+, White House Submit a correction requestReprints John Wilkerson Washington Correspondent John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. Newsletter The latest updates in federal health agencies, research institutes, and U.S. policy Recommended The Readout July 2, 2026 STAT Plus: Roche drug sets new standard for KRAS-driven lung cancer Adam's Biotech Scorecard July 2, 2026 STAT Plus: Halfway into the year, biotech is booming Advertisement Health tech July 2, 2026 STAT Plus: A former AI regulator, now in industry, says biopharma is reading FDA’s guidance wrong Biotech July 2, 2026 STAT Plus: A year after distressed buyout, what’s become of Bluebird Bio? In the Lab July 1, 2026 STAT Plus: Synthetic biology researchers think they’ve made a cell. Is it alive? Subscriber Picks